Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | BMP1 | P13497 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL464829 | 0.86 | ABCB1 (0.48) | MAPTABCB1BMP1HTTALOX5 | |
| SCHEMBL464754 | 0.82 | ABCB1 (0.45) | MAPTABCB1HTTMAOB | |
| SCHEMBL464753 | 0.82 | ABCB1 (0.45) | MAPTABCB1HTTMAOB | |
| SCHEMBL4343556 | 0.81 | BMP1 (0.41) | MAPTABCB1BMP1 | |
| SCHEMBL6619052 | 0.80 | ABCB1 (0.43) | MAPTABCB1HTT | |
| SCHEMBL13617894 | 0.79 | ABCB1 (0.47) | ABCB1 | |
| SCHEMBL6788036 | 0.78 | ABCB1 (0.45) | ABCB1ADAMTS4MMP2MMP13MMP14 | |
| SCHEMBL4347250 | 0.76 | MAOB (0.36) | MAPTABCB1BMP1HTTALOX5 | |
| SCHEMBL4345120 | 0.75 | ABCB1 (0.58) | ABCB1ADAMTS4MMP2MMP13MMP14 | |
| SCHEMBL4345123 | 0.75 | ABCB1 (0.58) | ABCB1ADAMTS4MMP2MMP13MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | SPINT2, DNPEP, PRSS1 | MAPT 1868/4885ABCB1 628/4885BMP1 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.